secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-127067
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics Q3 net loss $9.1M, cash $4.8M; FDA clears Phase 1 LM trial
----------------------------------------------------------------------------

- Net loss YTD Sep 30, 2024: $9.1M ($1.46 basic EPS) vs $9.5M ($3.54) prior year; operating loss $10.8M vs $9.5M.
- Cash and investments $4.8M at Sep 30, down from $8.6M at Dec 31, 2023; subsequent $0.9M DoD grant, $3.9M CPRIT grant expected.
- FDA agreed to initiate Phase 1 multi-dose trial of Rhenium(186Re) Obisbemeda for leptomeningeal metastases (LM); enrollment starts early 2025 at 7 U.S. sites.
- Completed enrollment in ReSPECT-GBM Phase 1 trial; presented positive data at CNS 2024; expanded sites to North Shore and Ohio State.
- Established GMP manufacturing partnership with SpectronRx for late-stage clinical and commercial supply of Rhenium(186Re) Obisbemeda.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000095017024127067/0000950170-24-127067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000095017024127067/pstv-20241114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-127067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer